ProCE Banner Activity

Expert Insights Into How Pathologists Can Guide Clinical Decision-making for HER2-Altered Solid Tumors

Clinical Thought

In this commentary, expert pathologists and oncologists answer questions about how pathologists can help guide clinical decision-making in patients with HER2-expressing or HER2-amplified solid tumors.

Released: April 23, 2024

Expiration: April 22, 2025

Share

Faculty

Katherine M. Bever

Katherine M. Bever, MD

Assistant Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Laura C. Collins

Laura C. Collins, MD

Vice Chair of Anatomic Pathology
Director of Breast Pathology
Beth Israel Deaconess Medical Center
Professor of Pathology
Harvard Medical School
Boston, Massachusetts

Tanya Gupta

Tanya Gupta, MD

Palo Alto Medical Foundation
Palo Alto, California

Funda Meric-Bernstam

Funda Meric-Bernstam, MD

Chair, Department of Investigational Cancer Therapeutics
Medical Director, Institute for Personalized Cancer Therapy
Nellie B. Connally Chair in Breast Cancer
Professor, Divisions of Cancer Medicine and Surgery
The University of Texas MD Anderson Cancer Center
Houston, Texas

Elizabeth D. Thompson

Elizabeth D. Thompson, MD, PhD

Associate Professor of Pathology and Oncology
Division of Surgical Pathology
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Jazz Pharmaceuticals, and Seagen.

AstraZeneca

Daiichi Sankyo, Inc.

Jazz Pharmaceuticals

Seagen

Disclosure

Primary Author

Katherine M. Bever, MD

Assistant Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Katherine M. Bever, MD: researcher: Bristol Myers Squibb, Merck Sharpe & Dohme.

Laura C. Collins, MD

Vice Chair of Anatomic Pathology
Director of Breast Pathology
Beth Israel Deaconess Medical Center
Professor of Pathology
Harvard Medical School
Boston, Massachusetts

Laura C. Collins, MD, has no relevant financial relationships to disclose.

Tanya Gupta, MD

Palo Alto Medical Foundation
Palo Alto, California

Tanya Gupta, MD: consultant/advisor/speaker: AstraZeneca, Biotheranostics, Gilead, Novartis, Pfizer.

Funda Meric-Bernstam, MD

Chair, Department of Investigational Cancer Therapeutics
Medical Director, Institute for Personalized Cancer Therapy
Nellie B. Connally Chair in Breast Cancer
Professor, Divisions of Cancer Medicine and Surgery
The University of Texas MD Anderson Cancer Center
Houston, Texas

Funda Meric-Bernstam, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, Black Diamond, Calibr (Scripps), Daiichi Sankyo, Dava Oncology, EcoR1, Eisai, Exelixis, GT Apeiron, Incyte, Infinity, Karyopharm, LegoChem Bio, Lengo Therapeutics, Menarini, OnCusp, Protai Bio, Seagen, Tallac Therapeutics, Theratechnologies, Zentalis, Zymeworks; researcher (paid to institution): Aileron Therapeutics, AstraZeneca, Bayer, Calithera Bioscience, Healthcare Pharmaceuticals.

Elizabeth D. Thompson, MD, PhD

Associate Professor of Pathology and Oncology
Division of Surgical Pathology
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Elizabeth D. Thompson, MD, PhD, has no relevant financial relationships to disclose.